Ann A Jakubowski
Overview
Explore the profile of Ann A Jakubowski including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
109
Citations
1984
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Shahid S, Prockop S, Flynn G, Mauguen A, White C, Bieler J, et al.
Blood Adv
. 2025 Feb;
PMID: 39908482
Despite clinical benefit with the use of CAR T-cells, the need to manufacture patient-specific products severely limits the clinical utility of this therapy. To overcome this barrier, we developed an...
2.
Han G, Stern A, Lee Y, Li Y, Dahi P, Tamari R, et al.
Transplant Cell Ther
. 2024 Dec;
31(2):105.e1-105.e9.
PMID: 39701288
We evaluated letermovir (LTV) for secondary prophylaxis for cytomegalovirus (CMV) in allogeneic hematopoietic cell transplant recipients (HCT) at high-risk for CMV recurrence. This open-label study was conducted at Memorial Sloan...
3.
Lin R, Dahi P, Korc-Grodzicki B, Shahrokni A, Jakubowski A, Giralt S
Curr Hematol Malig Rep
. 2024 Feb;
19(2):82-91.
PMID: 38332462
Purpose Of Review: Hematologic malignances more commonly affect older individuals and often present with advanced, higher risk disease than younger patients. Allogeneic and autologous hematopoietic cell transplantation is well-established treatment...
4.
Hollingsworth B, Aldrich J, Case Jr C, DiCarlo A, Hoffman C, Jakubowski A, et al.
Radiat Res
. 2023 Dec;
200(4):396-416.
PMID: 38152282
The hematopoietic system is highly sensitive to ionizing radiation. Damage to the immune system may result in opportunistic infections and hemorrhage, which could lead to mortality. Inflammation triggered by tissue...
5.
Dahi P, Kenny S, Flynn J, Devlin S, Ruiz J, Chinapen S, et al.
Leuk Lymphoma
. 2023 Sep;
64(14):2279-2285.
PMID: 37690007
This study aims to evaluate the predictive value of routine pulmonary function testing (PFT) at the 12-month mark post-autologous hematopoietic cell transplant (AHCT) in identifying clinically significant lung disease in...
6.
Nath K, Lee J, Elko T, Levy L, Preston E, Devlin S, et al.
Am J Hematol
. 2023 Sep;
98(12):1869-1876.
PMID: 37688521
Allogeneic hematopoietic cell transplantation (allo-HCT) is a potentially curative treatment for patients with acute leukemia. Despite this, studies have shown that only a minority of patients ultimately proceed to allo-HCT....
7.
Elias S, Brown S, Devlin S, Barker J, Cho C, Chung D, et al.
Br J Haematol
. 2023 Aug;
203(5):840-851.
PMID: 37614192
Comorbidity assessment before allogeneic haematopoietic cell transplantation (allo-HCT) is essential for estimating non-relapse mortality (NRM) risk. We previously developed the Simplified Comorbidity Index (SCI), which captures a small number of...
8.
Tamari R, Scordo M, Kunvarjee B, Proli A, Lin A, Flynn J, et al.
Blood Adv
. 2023 Jun;
7(18):5225-5233.
PMID: 37379285
Busulfan is an alkylating drug routinely used in conditioning regimens for allogeneic hematopoietic cell transplantation (allo-HCT). A myeloablative conditioning regimen, including busulfan, is commonly used in patients undergoing T-cell depletion...
9.
Elko T, Brown S, Lobaugh S, Devlin S, Jakubowski A, Perales M, et al.
J Adv Pract Oncol
. 2023 Apr;
14(2):127-137.
PMID: 37009407
Older patients with hematologic malignancies are increasingly considered for allogeneic hematopoietic cell transplant (allo-HCT). However, older patients often have increased comorbidities and thus may require an increased level of post-transplant...
10.
Cho C, Hilden P, Avecilla S, Barker J, Castro-Malaspina H, Giralt S, et al.
Adv Cell Gene Ther
. 2022 Nov;
4(1).
PMID: 36339371
Objective: To determine outcomes based on both disease- and patient-specific factors, we evaluated a prognostic model combining the Disease Risk Index (DRI) and Hematopoietic Cell Transplantation Comorbidity Index (HCT-CI), an...